Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma (PRIMAIN)
Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Gerald Illerhaus, PD Dr.
- Phone Number: +497612703785
- Email: Gerald.Illerhaus@uniklinik-freiburg.de
Study Contact Backup
- Name: Elvira Burger
- Phone Number: +497612707378
- Email: elvira.burger@uniklinik-freiburg.de
Study Locations
-
-
-
Freiburg, Germany, 79106
- Recruiting
- University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology
-
Contact:
- Gerald Illerhaus, PD Dr.
- Phone Number: +497612703785
- Email: Gerald.Illerhaus@uniklinik-freiburg.de
-
Contact:
- Elvira Burger
- Phone Number: +497612707378
- Email: elvira.burger@uniklinik-freiburg.de
-
Principal Investigator:
- Gerald Illerhaus, PD Dr.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- first diagnosis of PCNSL, histologically confirmed
- age > 65 years
- written signed and dated informed consent of the legal representative and - if possible - of the patient
Exclusion Criteria:
- manifestations of further lymphoma outside the CNS
- sero-positive for HIV
- severe pulmonary, cardiac, hepatic, renal impairment
- uncontrolled infection
- neutrophil count < 1.500/µl, platelet count < 100.000/µl
- pulmonary disease with IVC < 55%, DLCO < 40%
- cardiac ejection fraction < 50%, uncontrolled malign arrhythmia
- creatinine > 1,5 mg% or creatinine-clearance < 50ml/min
- bilirubin > 2mg/dl
- ascites or pleural effusion (> 500ml)
- known hypersensitivity against methotrexate, lomustine, procarbazine, rituximab, leukovorin, or dexamethasone
- participation in another clinical trial within the last 30 days prior to the begin or parallel to this study
- known or current drug or alcohol abuse
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Complete remission rate
Time Frame: 30 days after end of immuno-chemotherapy
|
30 days after end of immuno-chemotherapy
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Duration of response
Time Frame: within 5 years
|
within 5 years
|
|
Overall survival time
Time Frame: within 5 years
|
within 5 years
|
|
Neuropsychological state (according to Mini-Mental State and IPCG testing)
Time Frame: within 5 years
|
within 5 years
|
|
(Serious) adverse events ([S]AEs)
Time Frame: within 30 days after treatment
|
within 30 days after treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Gerald Illerhaus, PD Dr., University Medical Center Freiburg, Dept. of Internal Medicine I - Hematology and Oncology
Publications and helpful links
General Publications
- Illerhaus G, Marks R, Muller F, Ihorst G, Feuerhake F, Deckert M, Ostertag C, Finke J. High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol. 2009 Feb;20(2):319-25. doi: 10.1093/annonc/mdn628. Epub 2008 Oct 26.
- Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Mohle R, Low S, Binder M, Atta J, Keller U, Wolf HH, Krause SW, Hess G, Naumann R, Sasse S, Hirt C, Lamprecht M, Martens U, Morgner A, Panse J, Frickhofen N, Roth A, Hader C, Deckert M, Fricker H, Ihorst G, Finke J, Illerhaus G. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017 Apr;31(4):846-852. doi: 10.1038/leu.2016.334. Epub 2016 Nov 15.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Immunological
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Rituximab
- Methotrexate
- Lomustine
- Procarbazine
Other Study ID Numbers
Other Study ID Numbers
- 00591
- Eudract: 2008-007645-31
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.